Rolapitant Hydrochloride Patent Expiration

Rolapitant Hydrochloride is Used for prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy. It was first introduced by Tersera Therapeutics Llc in its drug Varubi on Sep 1, 2015.


Rolapitant Hydrochloride Patents

Given below is the list of patents protecting Rolapitant Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Varubi US9101615 Intravenous formulations of neurokinin-1 antagonists Jul 14, 2032 Tersera
Varubi US8361500 Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Oct 09, 2029 Tersera
Varubi US8470842 Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jan 18, 2029 Tersera
Varubi US7049320 NK1 antagonists Aug 19, 2028 Tersera
Varubi US7563801 Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr 04, 2027 Tersera
Varubi US7981905 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr 04, 2027 Tersera
Varubi US8178550 Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Apr 04, 2027 Tersera
Varubi US8404702 Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr 04, 2027 Tersera
Varubi US7049230 Method of forming a contact plug in a semiconductor device Dec 08, 2023

(Expired)

Tersera
Varubi US8796299 NK1 antagonists Dec 17, 2022

(Expired)

Tersera



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rolapitant Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Rolapitant Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 15 Nov, 2023 US8178550
Payment of Maintenance Fee, 8th Year, Large Entity 13 Feb, 2023 US9101615
Payment of Maintenance Fee, 12th Year, Large Entity 19 Jan, 2023 US7981905
Payment of Maintenance Fee, 8th Year, Large Entity 07 Feb, 2022 US8796299
Patent Term Extension Certificate 19 Nov, 2021 US7049320
Notice of Final Determination -Eligible 04 Mar, 2021 US7049320
Payment of Maintenance Fee, 8th Year, Large Entity 30 Sep, 2020 US8470842
Payment of Maintenance Fee, 12th Year, Large Entity 30 Sep, 2020 US7563801
Payment of Maintenance Fee, 8th Year, Large Entity 28 Sep, 2020 US8404702
Payment of Maintenance Fee, 8th Year, Large Entity 29 Jul, 2020 US8361500


Rolapitant Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List